Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early AD

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516565-36-00

Acronym

D20-P012

Enrollment

Registered

2024-11-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

10/12/2026

Detailed description

10/06/2027

Interventions

DRUGPROLEUKIN 18 millions U.I.

DRUGpoudre pour solution injectable

DRUGCHLORURE DE SODIUM 0

DRUG9 % B. BRAUN

DRUGsolution injectable en ampoule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
10/12/2026	—

Secondary

Measure	Time frame
10/06/2027	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026